Xencor (XNCR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Xencor (XNCR) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xencor's market cap?
Xencor (XNCR) has a market capitalization of approximately
What is Xencor's P/E ratio?
Xencor's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Xencor?
Xencor runs a net profit margin of -177.1%, a gross margin of 36.2%, and an operating margin of -217.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xencor generate?
Xencor reported revenue of
Does Xencor pay a dividend?
Xencor does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Xencor financially healthy?
Xencor carries a debt-to-equity ratio of 0.34x and a current ratio of 6.57x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Xencor a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xencor (XNCR) the key facts are: market cap
Track Xencor's full fundamentals live
Get Xencor's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.